A child with intellectual disability and dysmorphism due to complex ring chromosome 6: identification of molecular mechanism with review of literature

Frenny Sheth*, Thomas Liehr, Viraj Shah, Hillary Shah, Stuti Tewari, Dhaval Solanki, Sunil Trivedi and Jayesh Sheth

Abstract

Background: Ring chromosome 6 (r(6)) is a rare disorder that mainly occurs as a 'de novo' event. Nonetheless, a wide phenotypic spectrum has been reported in r(6) cases, depending on breakpoints, size of involved region, copy number alterations and mosaicism of cells with r(6) and/or monosomy 6 due to loss of r(6).

Case presentation: An 11-year-old male was referred with developmental delay, intellectual disability and microcephaly. Physical examination revealed additionally short stature and multiple facial dysmorphisms. Banding cytogenetic studies revealed a karyotype of mos 46,XY,r(6)(p25.3q27)[54]/45,XY,-6[13]/46,XY,r(6)(::p25.3→q27::p25.3→q27::)[13]/46,XY[6]/47,XY,r(6)(p25.3q27)x2[2]dn. Additionally, molecular karyotyping and molecular cytogenetics confirmed the breakpoints and characterized a 1.3 Mb contiguous duplication at 6p25.3.

Conclusion: The present study has accurately identified copy number alterations caused by ring chromosome formation. A review of the literature suggests that hemizygous expression of TBP gene in 6q27~qter, is likely to be the underlying cause of the phenotype. The phenotypic correlation and clinical severity in r(6) cases continue to remain widely diverse in spite of numerous reports of genomic variations.

Keywords: Molecular karyotyping, Molecular cytogenetics, Haploinsufficiency, Ring chromosome, R(6)

Background

Ring chromosome 6 (r(6)) is an exceedingly rare disorder, first described in 1973 by Moore et al. [1]. Since then, >30 patients with this condition have been reported [2]. Formation of ring chromosomes usually occurs due to breaks in the terminal portions of both the chromosome arms, followed by the fusion of broken ends. Alternatively, they can be formed by the union of subtelomeric sequences or telomere-telomere fusion with no deletion, resulting in a complete ring chromosome. Such complete rings without apparent significant loss of genetic material have been described in individuals with normal phenotypes [3]. Other mechanisms for ring chromosome formation, like terminal deletions, and/or contiguous inverted duplication due to an inv-dup-del rearrangement/s have also been proposed in the literature [4–6], also recently chromothripsis has been attributed as a possible reason for such cases [7].

Even though being rare, a wide spectrum of phenotypic variability is observed in all cases of autosomal ring chromosomes. Congenital heart defects, intellectual disability, microcephaly, facial dysmorphism, failure to thrive and various abnormalities in the ocular, auditory and central nervous systems are frequently detected [8].

In this study, a mosaic r(6) in a clinically abnormal, 11-year-old male was characterized in detail and compared with cases from the literature to share some new insights into the genotype-phenotype correlations.
Case presentation
An 11-year-old male was referred for further diagnostics due to developmental delay, intellectual disability and microcephaly. He was the first child born to apparently healthy non-consanguineous parents. The mother had an uneventful pregnancy with no history of prenatal exposure to alcohol, drug or tobacco. Though his siblings (7-year brother and 3 years old sister) were phenotypically normal, his paternal cousin-sister was microcephalic and mentally challenged. No investigations were carried out in the affected cousin-sister.

The proband was born by normal vaginal delivery. The birth weight was 1.5 kg and head circumference was 33 cm. Apgar score at birth was within the normal range. The patient was sitting without support at around 1.5 years. He could stand with support by 2 years and independent walking at 2.5 years. His speech development was delayed. He was not able to speak sentences and could not achieve proper bowel and bladder control even at the time of presentation (11 years). His height and weight were 108 cm and 14.5 kg respectively (below 10th centile); head circumference (OFC; Occipital Frontal Circumference) was 42 cm (below 3rd centile). The proband portrayed short stature and microcephaly with developmental delay. The facial dysmorphism showed long face, small chin, large protruding ears, slightly upturned eyes, sparse eyebrows, large bulbous nose and thin upper lip (Fig. 1a and b). Speech delay, penile chordee and sacral dimple were also noted during physical examination. His respiratory, cardiovascular and abdominal examinations were unremarkable. CNS examination showed intellectual disability, delayed language development and hyperactivity. His speech and cognitive development was more delayed than his motor milestones, and academic performance was very poor. His serum TSH (thyroid stimulating hormone) and GH (growth hormone) levels were normal. Magnetic resonance imaging (MRI; performed at an age of 10 years) showed demyelination in both frontal and parietal lobes (Fig. 2). Ultrasonography of abdomen and pelvis were normal, as were echocardiogram and ophthalmologic examinations.

Sample collection and written informed consent was obtained according to the need of the institutional ethics committee in accordance with Helsinki declaration. Chromosome analysis of the patient was performed with 72 h lymphocyte culture and standard GTG-banding. The karyotype was interpreted according to the International System for Human Cytogenetic Nomenclature (ISCN 2016) [9] as mos 46,XY,r(6)(p25.3q27)[54]/45,XY,-6[13]/46,XY,r(6)(::p25.3→q27::p25.3→q27::)[13]/46,XY[6]/47,XY,r(6)(p25.3q27)×2[2]dn (Fig. 3).

Karyotype of the parents was normal, confirming a ‘de novo’ origin of the r(6). Further analysis was carried out by molecular karyotyping using Affymetrix CytoScan™ 750 K array. Data was analyzed using Chromosome Analysis Suite (ChAS) and revealed: arr [GRCh37] 6pter>565,974,665,234)x1,6p25.3(668,700_1,929,528)x3,6q27qter(170,466,513_170,914,297)×1. In other words, there was a partial terminal monosomy of overall 508 kb in 6p25.3 followed by a 1.3 Mb contiguous duplication in 6p25.3 and 448 kb terminal deletion in 6q27 (Fig. 4). These results were
confirmed by fluorescence in situ hybridization (FISH) using commercially available subtelomeric probes for 6pter and 6qter. The duplicated region in 6p25.3 could not be confirmed by another method due to lack of corresponding locus-specific probes. The dicentric nature of double ring was thus established by a centromeric probe (Fig. 5).

Discussion and conclusions

Ring chromosome 6 is a rare event, that generally occurs as a ‘de novo’ event. Inheritance of ring chromosomes is quite infrequent since it is unstable during cell division with a possible loss of the ring during meiosis. Moreover, ring chromosome carriers may be infertile due to the chromosomal alteration.

Postnatal growth failure and microcephaly are the leading features of any autosomal ring chromosome; also they tend to show dynamic mosaicism, as observed in the present case. Patients with r(6) syndrome frequently present with growth retardation, facial dysmorphism and microcephaly. The additional clinical features of the present case can most likely be attributed to the cryptic duplication event in the r(6).

Major features associated either with 6p or 6q terminal deletions include defects of the anterior eye-chamber development, hearing loss, heart malformations, hypertelorism, mid-face hypoplasia, low set ears, developmental delay, intellectual disability, hypotonia, seizures, facial dysmorphism, and short neck [10, 11]. Most of these findings are analogous to that noted in the proband under report which suggests that the phenotypic variability and severity may partially be attributed to existence and instability of the ring. Several mechanisms for such instability are proposed in the literature, without plausible explanation [3, 12]. Further, the severity of the phenotype is hypothesized to be related to the size of the deletion. Microcephaly, facial dysmorphism and cardiac abnormalities seem to be more prevalent in the patients with single cell line anomaly; conversely, growth retardation, intellectual disability and demyelination of frontal and parietal lobes were additional anomalies that were more frequent with multiple cell lines.

To establish genotype/phenotype correlations for r(6), we compared the clinical features of the case under report to previously reported cases of r(6) (Table 1; Fig. 6) and explored the deleted and duplicated regions for morbid genes, using OMIM database and DECIPHER (https://decipher.sanger.ac.uk/).

The deleted 508 kb subtelomeric region from 6pter to 6p25.3 contains 4 annotated genes: DUSP22, IRF4, EXOC2, HUS1B; IRF4 (*601900) being the only OMIM morbid gene. Interferon regulatory factor 4 (IRF4) is a transcription factor essential for the development of T helper 2 (Th2), Th17 and Th9 cells, whose allelic variant influences variation in skin/hair/eye pigmentation 8. Dysregulation of IRF4 is associated with lymphoid malignancies [29].

The duplicated segment of 1.3 Mb at 6p25.3 was larger in size and contained more relevant OMIM genes-three
copies each of EXOC2, LOC285768, FOXQ1, FOXF2, FOXC1, GMDS, FOXCUT; FOXC1 being the only morbid gene amongst them. Mutations in Forkhead box C1; (FOXCI; *601090) has been associated with phenotypes like Anterior segment dysgenesis 3 and Axenfeld Reigen syndrome type 3. Nishimura et al. [30] in their study demonstrated that haploinsufficiency in addition to the mutations as well as increased gene dosage may cause anterior chamber defects of the eye. Later, Lehman et al. [31] reported an association between interstitial 6p25 duplications involving FOXC1 gene and ocular developmental abnormalities and glaucoma. Ophthalmologic examination in the patient under report did not reveal any abnormality and possibly point towards a less likely role of an extra copy of FOXC1 alone in the ophthalmological manifestations in such patients.

Apart from ocular manifestations, mutations and haploinsufficiency of FOXC1 gene have also been speculated to be implicated in cardiac abnormalities [2, 32]. However, there seem to be no reports to suggest for duplication. The patient under report had normal echocardiography findings. There is a paucity of data on the pathological manifestations of distal 6p duplication. Qi et al. elaborated on the same in 2015 study and concluded that copy number gain of this particular region is likely benign or triploinsensitive [33].

A terminal deletion (448 kb) was detected (from 6q27 to 6qter) that encompass LOC154449, DLL1, FAM120B, MIR4644, PSMB1, TBP, PDCD2 OMIM annotated genes. Amongst them, TATA-binding protein (TBP), a general transcription factor associates with aggregates in several polyglutamine disorders; is the only gene with a pathogenic potential [34]. A reasonable number of studies have postulated TBP as a potential candidate gene responsible for the phenotype of patients with subtelomic 6q deletions, irrespective of the size of terminal deletion [35, 36]. Moreover, a study [37] has reported a ‘de novo’ missense mutation in the chromosome 6 open reading frame 70 (C6orf70) gene in 1/14 (7.1%) patient with periventricular nodular heterotopia, developmental delay and epilepsy through whole exome sequencing. In addition, the authors silenced C6orf70 and two additional genes (phf10 and Dll1) in the developing rat neocortex and suggested that C6orf70 plays a major role
Table 1: Comparative clinical features and cytogenetic results in various cases of ring chromosome 6

| Publications          | Single cell line (one of the chromosome #6 has been replaced by a ring chromosome 6) | Fraction |
|-----------------------|-------------------------------------------------------------------------------------|----------|
|                       |                                                                                     |          |
| Karyotype             |                                                                                     |          |
| Not available         | 46,XX, r(6)(p25q27)                                                              | 6/7      |
| Clinical features     |                                                                                     |          |
| Microcephaly          | √                                                                                    |          |
| Facial dysmorphism    | √                                                                                    | 5/7      |
| Glaucoma              | √                                                                                    |          |
| Hearing loss          | √                                                                                    | 3/7      |
| Tachypnea             | –                                                                                    |          |
| Speech delay          | –                                                                                    |          |
| White matter abnormalities in brain |                                                                  |          |
| Developmental delay   | √                                                                                    | 3/7      |
| Growth retardation    | √                                                                                    | 3/7      |
| Intellectual disability |                                                                  | 2/7      |
| Scoliosis             | √                                                                                    | 1/7      |
| Cardiac anomalies (ASD,CHD,PDA) |                                                                  | 3/7      |
| Abnormalities in the digits (brachydactyly/clinodactyly/bilateral syndactyly) | | 3/7      |
| Single palmar crease  | √                                                                                    | 1/7      |
| Penile chordee        | –                                                                                    |          |
| Sacral dimple         | –                                                                                    |          |
| Abnormalities in the foot |                                                                  | 1/7      |
| Complex bone disorders |                                                                  | –        |
| Dry skin              | √                                                                                    | 1/7      |
| seizures              | √                                                                                    | 3/7      |
| Umbilical hernia      | √                                                                                    | 1/7      |

ASD atrial septal defect, CHD congenital heart defect, PDA patent ductus arteriosus
| Mosaicism (structural and numerical variants of ring chromosome #6 are present in various cell lines in different proportions) | 2 cell lines | 3 cell lines | 4 cell lines | 5 cell lines | Present case | Fraction |
|---|---|---|---|---|---|---|
| Publications | Hurd et al. [20] | Lee et al. [8] | Andrieux et al. [21] | Kara et al. [22] | Nishigaki et al. [23] | Hockner et al. [24] | Nishi et al. [25] |
| Karyotype | 47, XY, +17[4]/48, XY, +r [2] and second case | 46, XY, +r(6)[p25q27]/46, XY, dic r(6)(p25q27);p25q27 | 46XY,r(6)(p25q27)/45XY-6 | mos46XY,r(6)[p24q26],del(6)[q27] | 30/46XY,r(6)[p25q27];del(6)[q27] | mos 46,XX,r(6)[p25q27]/45,XX,r(6)[p25q27];del(6)[q27] | mos 46,XY,r(6)[p25q27];del(6)[q27] | Not available |
| Clinical features | | | | | | | |
| Microcephaly | √ | √ | √ | √ | √ | √ | √ | 7/8 |
| Facial dysmorphism | √ | √ | √ | √ | √ | √ | √ | 7/8 |
| Glaucoma | | | | | | | | |
| Hearing loss | | | | | | | | |
| Tachypnea | | | | | | | | 1/8 |
| Cardiac anomalies (ASD,CHD,PDA) | | | | | | | | |
| Single palmar crease | | | | | | | | |
| Penile chordee | | | | | | | | |
| Sacral dimple | | | | | | | | |
| Abnormalities in the foot | | | | | | | | 1/8 |
| Abnormalities in the digits (brachydactyly/clinodactyly/bilateral syndactyly) | | | | | | | | 1/8 |

Table 1 Comparative clinical features and cytogenetic results in various cases of ring chromosome 6 (Continued)
| Feature                  | Cases (n) | Count |
|-------------------------|-----------|-------|
| Complex bone disorders  | √ (2)     | 2/8   |
| Dry skin                | –         | –     |
| Seizures                | √ (2)     | –     |
| Umbilical hernia        | –         | –     |

*(Continued)*
in the control of neuronal migration and its haploinsufficiency or mutation causes periventricular heterotopia.

Developmental delay, intellectual disability, dysmorphism, seizures, dimpling of elbows and knees are some of the main features noted in such patients. Most of the above mentioned clinical features were also seen in our patient, raising a strong possibility pointing towards the hemizygous expression of TBP might be implicated in the causation of the phenotype. Apart from these, the developmental delay, growth stunting and mild facial dysmorphism observed in the proband can also be attributed partially to the mitotic instability of the ring chromosome as the source of continuous production of secondary aneuploid cells [3, 25]. There is still a dearth of literature on ring chromosome 6 and therefore, further studies are advocated to understand the role of genes influencing such genotype-phenotypic presentations.

Abbreviations
DLL1: Delta like canonical notch ligand 1; DUSP22: Dual specificity phosphatase 22; EXOC2: Exocyst complex component 2; FAM120B: Family with sequence similarity 120B; FISH: Fluorescence in situ hybridization; FOXC1: Forkhead box C1; FOXCUT: FOXC1 upstream transcript; FOXF2: Forkhead box F2; FOXQ1: Forkhead box protein Q1; GMDS: GDP-mannose 4,6-dehydratase; HUS1B: HUS1 checkpoint clamp component B; IRF4: Interferon regulatory factor 4; ISCN: International System for Human Cytogenetic Nomenclature; MIR4644: MicroRNA 4644; PDCD2: Programmeed cell death 2; PSMB1: Proteasome subunit beta type-1; r(6): Ring chromosome 6; SNP: Single nucleotide polymorphism; TBP: TATA-binding protein

Acknowledgements
We would like to express our sincere thanks to Dr. Krati Shah for critical reading. We are grateful to the family of the patient for their kind cooperation and permission. We acknowledge the Gujarat State Biotechnology Mission (GSBTM) [Grant no.: GSBTM/MD/PROJECTS/SSA/505/4865/2016–17] for partly supporting the work.

Funding
This work is partly supported by Gujarat State Biotechnology Mission (GSBTM) [Grant no.: GSBTM/MD/PROJECTS/SSA/505/4865/2016–17]. The funding agency was not directly or indirectly involved in the study design, specimen collection, analysis, interpretation and preparation of the manuscript.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions
Conceived and designed the experiments: FS. Clinical analysis: DS. Cytogenetic and Molecular analysis: FS and TL. Wrote the first draft of the manuscript: HS, VS, ST. Made critical revisions and approved final version: JS, ST. All authors reviewed and approved of the final manuscript.

Ethics approval and consent to participate
• Present case under submission has been approved by the institutional ethics committee [FRIGE’s Institute of Human Genetics] wide approval number FRIGE/IEC/15/2016 dated 16th March, 2016. This process is in accordance with the Helsinki declaration.
• An informed consent was obtained from the parents before enrolling for the investigations [This was in accordance with the requirement of the institutional ethics committee].
• An informed consent for publication was also obtained from the parents [This was in accordance with the need of the institutional ethics committee].
Consent for publication
Written informed consent was obtained from patient’s parents for publication of their clinical details. A copy of the written consent is available for review.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Moore CM, Heller RH, Thomas GH. Developmental abnormalities associated with a ring chromosome 6. J Med Genet. 1973;10:299–303.
2. Zhang R, Chen X, Li P, Lu X, Liu Y, Li Y, et al. Molecular characterization of a novel ring 6 chromosome using next generation sequencing. MolCytogenet. 2016;9:33. https://doi.org/10.1186/s13039-016-0245-9.
3. Yip MY, Genetics Laboratory. Autosomal ring chromosomes in human genetic disorders. In: TransPediatr; 2015. https://doi.org/10.3978/j.issn.2224-4336.
4. Seghezzi L, Maraschio P, Bozolla M, Maserati E, Tuppler R, Marchi A, et al. Ring chromosome 9 with a 9p22.2-p24.3 duplication. Eur J Pediatr. 1990;159:791–3.
5. Knijnenburg J, van Haeringen A, Hansson KB, Lancaster A, Smit MJ, Belfroid RD, et al. Ring chromosome formation as a novel escape mechanism in patients with inverted duplication and terminal deletion. Eur J Hum Genet. 2007;15:548–55.
6. Rossi E, Regezi M, Messa J, Ginelli S, Maraschio P, Ciccone R, et al. Duplications in addition to terminal deletions are present in a proportion of ring chromosomes as a mechanism of formation. J Med Genet. 2008;45:147–54.
7. Kurtas N, Anigoni F, Erichello E, Zucca C, Maghini C, D’Angelo MG, et al. Chromatid recombination and ring chromosome 22. A paradigm of genomic complexity in the Phelan-McDermid syndrome (22q13 deletion syndrome). J Med Genet. 2011;48(4):269–77.
8. Lee S, Kyun Han D, Cho H, Cho YK, Ma JS. Mosaic ring chromosome 6 in an infant with significant patent Ductus Arteriosus and multiple congenital anomalies. J Korean Med Sci. 2012;27:948–52.
9. Mc Gowen-Jordan J, Simons A, Schmid M. An international system for published maps and institutional affiliations.
10. Bogani D, Willoughby C, Davies J, Kaur K, Mirza G, Paudyal A, et al. Characterisation of a de novo ring chromosome 6 involving a terminal 6p deletion and terminal 6q duplication in the different arms of the same chromosome. MolCytogenet. 2017;10:99. https://doi.org/10.1186/s13039-017-0311-y.
11. Ciocca L, Sunace C, Digilio MC, Roberti MC, Sirleto P, Lombardo A, et al. Array-CGH characterization and genotype-phenotype analysis in a patient with a ring chromosome 6. BMC Med Genet. 2013;63: https://doi.org/10.1186/1758-2946-6-3.
12. Guilherme RS, Meloni VFA, Kim CA, Pellegrino R, Takeno SS, Spinner NB, et al. Molecular cytogenetic characterisation of a novel de novo ring chromosome 6 involving a terminal 6p deletion and terminal 6q duplication in the different arms of the same chromosome. MolCytogenet. 2017;10:99. https://doi.org/10.1186/s13039-017-0311-y.
13. Ahsad HA, Ramli SF, Loong TM, Salashshoufia J, Ziffal BA, Yusoff NM. De novo ring chromosome 6 in a child with multiple congenital anomalies. Kobe J Med Sci. 2010;56:E79–84.
14. Walker ME, Salamon DAL, Milatovich A, Saal HM. Prenatal diagnosis of ring chromosome 6 in a fetus with hydrocephalus. PrenatDiagn. 1996;16:857–61.
15. Kini KR, Van Dyke DL, Weiss L, Logan MS. Ring chromosome 6: case report and review of literature. Hum Genet. 1979;50:145–9.
16. Fried K, Rosenblat M, Mundel G, Kikker R. Mental retardation and congenital malformations associated with a ring chromosome 6. Clin Genet. 1975;7:192–6.
17. Zhang HZ, Li P, Wang D, Huffs NM, Qumsiyeh M, et al. FOXC1 gene deletion is associated with eye anomalies in ring chromosome 6. Am J Med Genet A. 2004;124A:280–7.
18. Hurd LM, Thacker MM, Okenfuss E, Duke AL, Lou Y, Harty MP, et al. Aneurysmal bone cysts and pathologic fracture associated with supernumerary ring chromosome 6 in two unrelated patients. Am J Med Genet A. 2017. https://doi.org/10.1002/ajmg.a.38498.
19. Andreijs J, Devisme L, Valat KS, Robert Y, Frikka C, Savayo JB. Prenatal diagnosis of ring chromosome 6 in a fetus with cerebellar hypoplasia and partial agenesis of corpus callosum: case report and review of the literature. Eur J Med Genet. 2005;199:206.
20. Kara N, Oktan G, Gunay SQ, Saglam Y, Tasdemir HA, Pinarli FA. An epileptic case with mosaic ring chromosome 6 and 6q terminal deletion. Epilepsy Res. 2008;80(2–3):219–23. https://doi.org/10.1016/j.eplepsies.2008.03.020.
21. Nishiyak S, Hamazaki T, Saito M, Yamamoto T, Seto T, Shintaku H. Periventricular heterotopia and white matter abnormalities in a girl with mosaic ring chromosome 6. MolCytogenet. 2015;8:54. https://doi.org/10.1186/s13039-015-0162-3.
22. Hockner M, Utermann B, Eredal M, FauthC, Utermann G, Kotzot D. Molecular characterization of a de novo ring chromosome 6 in a growth retarded but otherwise healthy woman. Am J Med Genet. 2008;146A:925–9.
23. Ishii Y, Yoshimura O, Ohama K, Usui T. Ring chromosome 6: case report and review. Am J Med Genet A. 1982;12:109–14.
24. Linhares ND, Svartman M, Rodrigues TC, Rosenberg C, Valadares ER. Subtelomeric 6p25 deletion/duplication: report of a patient with new clinical findings and genotypephenotype correlations. Eur J Med Genet. 2015;58(5):310–8.
25. Miho CP, Benitez J, Ayuso C, Cascos SA. Ring chromosome 6: clinical and cytogenetic behaviour. Am J Med Genet 1990;35(4):481–3.
26. Camevate A, Banco B, Castillo J, Castillo V, Dominguez R. Ring chromosome 6 in a child with minimal abnormalities. Am J Med Genet. 1979;4271–7.
27. Nam S, Lim JS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res. 2016. https://doi.org/10.1007/s12012-016-0854-1.
28. Nishimura DY, Seaby CC, Alward WL, Walton D, Craig IE, Mackey DA, et al. Spectrum of FOXC1 mutations suggests gene dosage as a mechanism for developmental defects of the anterior chamber of the eye. Am J Hum Genet. 2001;68:364–72.
29. Lehmann DJ, Ebenezer ND, Ekong R, Ocaka L, Mungall AJ, Fraser S, et al. Ocular developmental abnormalities and glaucoma associated with interstitial 6p25 duplications and deletions. Invest Ophthalmol Vis Sci. 2002;43:1843–9.
30. Seo S, Kume T. Forkhead transcription factors, Foxc1 and Foxc2, are required for the morphogenesis of the cardiac outflow tract. Dev Biol. 2006;294:211–36.
31. Qin Z, Li B, Slavotnek A, Yu J. Haploinsufficiency and triploinsensitivity of the same 6p25.1p24.3 region in a family. BMC Med Genet. 2015;58:38. https://doi.org/10.1186/s12881-015-0113-1.
32. Roon WM, Reid MJ, Faull RM, Snell RG. TATA-binding protein in neurodegenerative disease. Neuroscience. 2005;133:863–72.
33. Rooms L, Reynolds E, Scheers S, Luijk RV, Wauters J, Aerschot LV, et al. TBP as a candidate gene for mental retardation in patients with subtelomeric 6q deletions. Eur J Hum Genet. 2006;10:1090–8.
34. Esh D, Waggoner D, Chung J, Stevenson D, Martin C. Calibration of 6q subtelomere deletions to define genotype/phenotype correlations. Clin Genet. 2005;67(5):396–403. https://doi.org/10.1111/j.1399-0004.2005.00424.x.
35. Conti V, Carabalona A, Pallesci-Pocachard E, Panini E, Leverentz RJ, Buhler E, et al. Periventricular heterotopia in 6q terminal deletion syndrome: role of the C6orf70 gene. Brain. 2013;136:3378–94. https://doi.org/10.1093/brain/awt249.